About alpelisib
PI3K-alpha inhibitor
Used for
- With fulvestrant for hormone receptor-positive, HER2-negative advanced breast cancer with a PIK3CA mutation, after progression on endocrine therapy.
Usual adult dose
Usual dose is 300 mg by mouth once daily with food; continue with fulvestrant until progression or unacceptable side effects.
Common side effects
- High blood sugar
- Diarrhea
- Rash
- Nausea and decreased appetite
Important warnings
- Can cause severe high blood sugar, including diabetic ketoacidosis.
- Serious skin reactions and severe diarrhea or colitis can occur.
- Lung inflammation has been reported; new breathing problems need prompt assessment.
- Testing for a PIK3CA mutation is required before treatment.
Pregnancy
May harm an unborn baby. Pregnancy testing and effective contraception are recommended during treatment and for one week after the last dose.
Breastfeeding
Do not breastfeed during treatment and for one week after the last dose.
Interactions
- Strong CYP3A4 inducers can lower alpelisib levels and reduce its effect.
- BCRP inhibitors can increase alpelisib exposure; avoid or monitor closely.
- Alpelisib may increase exposure to medicines handled by BCRP, including some statins.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.